James B. Weissman joined Dicerna as chief business officer in January 2012 and was appointed chief operating officer and executive vice president in September 2019. He has more than 30 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing and M&A activities. Mr. Weissman serves on the board of Receptor Holdings, Inc.

Prior to Dicerna, Mr. Weissman was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Prior to MannKind, Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In that position, he was responsible for the sales, profit and strategic targets for the company’s specialty products, including central nervous system (CNS), endocrinology, ophthalmology and oncology therapeutics and diversified portfolios.

Mr. Weissman holds a Bachelor of Science degree from Bates College.

Ralf Rosskamp, M.D., joined Dicerna as chief medical officer in June 2017, and is responsible for leading the Company’s clinical development, medical affairs and regulatory functions. Dr. Rosskamp has more than 20 years of research and development (R&D) experience spanning the entire drug development cycle, from pre-clinical through product commercialization. 

Prior to joining Dicerna, Dr. Rosskamp was chief medical officer at Summit Therapeutics. In this role, he directed and oversaw all clinical development and medical activities for Summit’s investigational therapies for the rare genetic disease Duchenne muscular dystrophy and the infectious disease caused by Clostridium difficile bacteria. Prior to Summit, Dr. Rosskamp held executive-level positions in clinical research and drug development at NPS Pharmaceuticals (acquired by Shire), Ikaria, Kos Pharmaceuticals (acquired by Abbott Laboratories), Aventis Pharmaceuticals (formerly Hoechst Marrion Roussel), and Hoechst AG.

Dr. Rosskamp has been responsible for numerous investigational new drug applications, the design and execution of clinical development programs, and new drug applications across multiple therapeutic areas including diabetes, cardiovascular, respiratory and orphan drugs. He was involved in the development of several approved products including Amaryl^®, Lantus^®, Apidra^®, Simcor^® and Natpara^®.

Dr. Rosskamp is a member of the Board of Directors of Bioblast Pharma in Tel Aviv, Israel. He has authored more than 20 peer-reviewed publications and published more than 50 scientific abstracts. Dr. Rosskamp is a pediatric endocrinologist with more than 15 years of experience in clinical medicine. He received his M.D. from the University of Bonn, Germany.

David Miller, Ph.D., is senior vice president, corporate operations/ alliance management at Dicerna Pharmaceuticals, which he joined in 2008. Over the course of his career, he has successfully combined leadership roles in both business and research capacities. He has been a member of five early-stage biotech companies, each of which has successfully transitioned to a public company. 

At Dicerna, Dr. Miller has also served as vice president of research operations and of business development.  Previously, he was senior director, business development at Synta Pharmaceuticals, where he had partnering responsibility for the company’s oncology portfolio and played a lead role in a pharma partnership, valued at over $1 billion.  Prior to Synta, he was director, business development at Altus Biologics, where his responsibilities included developing the drug delivery business and the partnering of several biological products.  Dr. Miller was a founder and the head of research for EcoScience Corporation, an agricultural biotechnology company. He began his career at Genetics Institute. Dr. Miller is the inventor on six issued United States patents.  He is a board member of EcoPesticides International, a New Mexico company, and serves on several public boards in his hometown of Winchester, Mass.

Dr. Miller holds a Ph.D. in molecular biology and biochemistry from Harvard University and a B.S. in biochemistry and biophysics from the University of California, Davis.

Jennifer Lockridge, Ph.D., is senior vice president of program development at Dicerna Pharmaceuticals and has 20 years of experience in the development of oligonucleotide therapeutics. Prior to joining Dicerna, Dr. Lockridge spent nine years consulting with multiple biotech and large pharmaceutical companies to provide direction and support for early development-stage oligonucleotide programs as well as pharmacology and pharmacokinetics expertise.

From 1996 to 2007, Dr. Lockridge was employed at Sirna Therapeutics, Inc. (formerly Ribozyme Pharmaceuticals, Inc.).  As director of project management at Sirna, she managed and was involved with all aspects of siRNA and ribozyme development programs.

Dr. Lockridge received her Ph.D. in pharmacology from the Oregon Health Sciences University in Portland and completed postdoctoral training at the FDA’s National Center for Toxicological Research in Jefferson, Ark.

Jack Green joined Dicerna as chief financial officer in April 2016. Mr. Green is a CPA and accomplished finance executive with more than three decades of senior financial management experience. He spent most of these as chief financial officer of publicly traded biotechnology companies.

Prior to Dicerna, Mr. Green was chief financial officer of Verastem, Inc., an oncology-focused biotechnology company. He served for more than 15 years as chief financial officer of GTC Biotherapeutics, Inc. a stand-alone public company and spinoff from Genzyme Corporation.

Mr. Green received his bachelor’s degree from the College of the Holy Cross, where he majored in economics and accounting, and his M.B.A. in business administration from the Boston University Graduate School of Management.

Douglas Fambrough co-founded Dicerna in 2007 and has served as the Company’s president and chief executive officer since 2010. His background as both a genomic scientist and venture capitalist have been instrumental in the evolution of the Company, from the development of its unique GalXC™ platform to its transformation into a successful, publicly traded company.

Prior to Dicerna, Dr. Fambrough specialized in financing innovative life science technology companies as a general partner with Oxford Bioscience Partners, a Boston-based venture capital firm.

In 2003, Dr. Fambrough and two other investors created Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s board of directors until Merck acquired the company in 2006. On Oxford’s behalf, Dr. Fambrough invested in several ventures, including: Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, which Illumina acquired, and Xencor, a leader in engineering antibodies to improve their therapeutic properties (Nasdaq: XNCR).

Before joining Oxford Bioscience Partners, Dr. Fambrough spent 10 years as a genomic scientist, most recently at the Whitehead/MIT Center for Genome Research, now known as the Broad Institute. He graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.

Regina DeTore Paglia is the senior vice president of human resources and has more than 25 years of experience in human resources management at numerous biopharmaceutical, biochemical, and managed care companies from early-stage start-up to full commercial operations.

Most recently, she was senior vice president of human resources at Paratek Pharmaceuticals, reporting directly to the chief executive officer and chairman as a member of the executive leadership team. Prior to that, she was vice president (2010-12) and senior vice president (2012-15) of human resources at Myriant Corporation, a biochemical company that is a subsidiary of PTTGC Global Chemical Company. From 2008 to 2010, Ms. Paglia was vice president of human resources at Mascoma Corporation, a biofuels company. She has also held several executive positions in human resources at Sepracor Pharmaceuticals and Tufts Health Plans.

Ms. Paglia is the 2018 recipient of the Bob Gatti HR Leadership Excellence Award of Distinction from the Human Resources Leadership Forum. She holds a bachelor’s degree in business management and marketing from Sawyer Business School at Suffolk University in Beacon Hill, Mass., and a master’s degree in human resources management from Framingham (Mass.) State College.

Rob Ciappenelli joined Dicerna as chief commercial officer in 2019, with nearly three decades of experience working across the pharmaceutical and biotech- industries. His expertise spans rare diseases, neurological disorders, and diseases of the respiratory and gastrointestinal systems.

Most recently, he was global head of commercial at Momenta Pharmaceuticals. In that capacity, Mr. Ciappenelli managed a portfolio of 13 programs ranging from early development to partnered in-market products.

Prior to Momenta, he held several leadership positions at Shire Pharmaceuticals (now part of Takeda), across commercial operations and business planning. He led global franchise operations for Shire’s Fabry (Replagal^®) and Gaucher (Vpriv^®) programs. Mr. Ciappenelli’s pharmaceutical commercialization experience also includes leadership positions at Sunovion Pharmaceuticals, where he served as vice president of commercial operations, executive director of commercial services and sales training, and executive director of central nervous system marketing.

Bob Brown joined Dicerna as senior vice president, research in 2008. Prior to joining Dicerna, he had a successful career at former biopharmaceutical company Genta, where he was vice president, research and technology.

While at Genta, he amassed more than 75 patents and patent applications. Dr. Brown became one of the only executives in the biotechnology industry to follow a systemically administered oligonucleotide therapeutic (Genasense™) from the research bench through Phase 3 clinical trials and regulatory review. He worked directly with clinicians and study investigators on trial design, execution and interpretation, of results.

In addition to his roles at Genta, Dr. Brown was co-founder and vice president of research and development at Oasis Biosciences.

Dr. Brown holds a B.S. in chemistry and biology from the University of Washington and Ph.D. in molecular biology from the University of California, Berkeley.